EliA assays combine exceptional specificity with highest sensitivity and provide the guidance and safety clinicians need for their daily diagnostic decisions. Most important, the positive predictive values and likelihood ratios of our EliA assays give excellent values assuring high clinical usefulness in routine practice.
- “Phadia EliA dsDNA assay provides the best specificity, positive predictive value and post-test probability in the study.”
Antico, Lupus 2010
- “…. a positive result by EliA CTD Screen had a higher likelihood ratio than a positive result by indirect immunofluorescence.”
Op de Beeck, Autoimmun Rev 2011
- “… IgA anti-tTG assay from Phadia had the highest likelihood ratio in this study.”
Vermeersch P., Clin Chim Acta 2010
- “Importantly, positive predictive values of the automated tests (85.2%) in comparison to the CCP IgG 3.0 manual ELISA (72.5%) resulted in a better correlation with clinical RA.”
Elfrefaei, J.Clin. Immunol. 2011
For many tests quantitative results enable estimations on the severity and the prognosis of the disease. Quantitative results therefore have a higher clinical value than qualitative results which solely point out if the test result is ‘positive’ or ‘negative’.
By offering specific markers (e.g., EliA dsDNA) which are appropriate for the follow-up of patients medical doctors can benefit from support in patient management.
- "Follow-up of SLE patients with nephritis showed good correlation between flare and dsDNA antibodies by EliA dsDNA."
Poster Viander M. et al. 5th International Congress on Autoimmunity, Sorrento, Nov. 2006
- "EliA dsDNA detects anti-dsDNA antibodies in patients with renal involvement more frequently and with a significantly higher mean titer compared to patients without this complication."
Vilalta D. et al., J Clin Lab Anal 2002, 16: 227-232